Skip to Main Content

Top of the morning to you. The middle of the week is upon us and, since you made it this far, why not forge ahead? After all, there is always light at the end of the proverbial tunnel. You never know what you may accomplish. As for us, we will be splitting our time today between the usual foraging and moderating a panel. Meanwhile, we have assembled a menu of tidbits to help you along on your own journey. So please dig in. Have a smashing day and please feel free to forward any secrets you come across. Our in-basket is always open. …

Novartis (NVS) won U.S. regulatory approval for its new multiple sclerosis drug Mayzent, which targets patients whose disease has shifted from intermittent attacks to a gradually worsening progression, Reuters writes. The drug will have an $88,000 list price, which is “well above commonly cited thresholds for cost-effectiveness,” according to the Institute for Clinical and Economic Review. Nonetheless, this is less than rival MS drugs, and because it’s the only drug approved for secondary progressive MS, Jefferies analyst Peter Welford forecasts peak annual worldwide sales of $1.25 billion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Hmmm, insert alternate word – “In January, Trump said that he expected [ insert ______ ] to see a tremendous decrease in drug prices…” What would it be? Free-wheeled, fantacised, hallucinated, prevaricated, or simply ‘made fake news?’

Comments are closed.